{
  "source": "PA-Notification-Retinoids.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1089-13\nProgram Prior Authorization/Notification - Topical Retinoid Products\nMedication Topical Retinoid Products\nAltreno® (tretinoin)*, Arazlo®, (tazarotene)*, Avita® (tretinoin)*,\nAtralin® (tretinoin)*, Retin-A® (tretinoin) [brand only]*, Retin-A\nMicro® (tretinoin microspheres)*, Differin® (adapalene)*, Fabior®\n(tazarotene)*, Tazorac® (tazarotene), and Aklief® (trifarotene)\nP&T Approval Date 2000, 3/2006, 2/2007 3/2007, 10/2008, 10/2009, 5/2010, 5/2011,\n7/2012, 7/2013, 11/2013, 8/2014, 7/2015, 6/2016, 2/2017, 2/2018,\n1/2019, 1/2020, 6/2020, 4/2021, 4/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nTopical retinoid products are indicated for cosmetic and medical conditions (e.g., acne vulgaris,\npsoriasis, precancerous skin lesions). Cosmetic use is not a covered benefit per the\nUnitedHealthcare pharmacy Rider. Therefore, Prior Authorization/Notification is in place to\nverify the use is for the diagnosis of a medical condition. For covered medications, if members\nare younger than 30 years of age the topical retinoid prescription will automatically adjudicate\nwithout a coverage review.\n2. Coverage Criteria:\nA. Topical Retinoid Products will be approved based on both of the following:\n1. The member has a non-cosmetic medical condition (e.g., acne vulgaris, psoriasis,\nprecancerous skin lesions, other conditions listed below, etc.)\nAcanthosis nigricans Keratoderma\nAcne Keratoderma palmaris et plantaris\nAcne keloidalis nuchae Keratosis rubra figurata\nAcne rosacea Kyrle’s disease\nAcne vulgaris Lamellar ichthyosis\nActinic cheilitis Leukoplakia\nActinic dermatitis Lichen planus\nActinic keratosis Mal de Meleda\nBasal cell carcinoma Malignancy\nBowen’s disease Mendes da Costa syndrome\nCystic acne Molluscum contagiosum\nDarier’s disease Non-bullous congenital ichthyosis\nDarier-White Disease Papillon-Lefevre syndrome\nDermal mucinosis Porokeratosis\nDiscoid lupus erythematosus Pseudofollicular ba",
    "e Molluscum contagiosum\nDarier’s disease Non-bullous congenital ichthyosis\nDarier-White Disease Papillon-Lefevre syndrome\nDermal mucinosis Porokeratosis\nDiscoid lupus erythematosus Pseudofollicular barbae\nEpidermoid cysts Pseudoacanthosis nigricans\nEpidermolytic hyperkeratosis Psoriasis\n© 2024 UnitedHealthcare Services, Inc.\n1\nErythrokeratoderma Psoriasis erythrodermic,\nvariabilis palmoplantar\nFavre Racouchot disease Psoriasis pustular\nFlat warts Psoriatic arthritis\nFolliculitis Rosacea\nFox Fordyce disease Sebaceous cysts\nGrover’s disease Senile keratosis\nHidradenitis suppurativa Solar keratosis\nHyperkeratosis Squamous cell carcinoma\nHyperkeratosis follicularis Transient acantholytic dermatosis\nHyperkeratotic eczema Tylotic eczema\nIchthyoses X-linked ichthyosis\nIchthyosis vulgaris Verruca plana\nKeratoacanthoma Von Zumbusch pustular\nKeratosis follicularis Warts\n-AND-\n2. Medication is not being requested solely for cosmetic purposes (e.g., photoaging,\nwrinkling, hyperpigmentation, sun damage, melasma)\nAuthorization will be issued for 12 months.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n*Altreno, Arazlo, Avita, Atralin , Aklief, Retin-A gel, Retin-A cream (brand only), Retin-A\nMicro, Differin, and Fabior are typically excluded from coverage.\n4. References:\n1. Atralin [package insert]. Bridgewater, NJ: Bausch Health US, LLC.; February 2024.\n2. Avita cream [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; June 2018.\n3. Differin gel [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; August 2022\n4. Differin lotion [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; April 2023.\n5. Differin cream [package insert]. Fort Worth, TX: Gald",
    "rth, TX: Galderma Laboratories, L.P.; August 2022\n4. Differin lotion [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; April 2023.\n5. Differin cream [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; October 2022.\n6. Retin-A [package insert]. Bridgewater, NJ: Bausch Health US, LLC.; March 2024.\n7. Retin-A Micro [package insert]. Bridgewater, NJ: Bausch Health US, LLC.; October 2023.\n8. Tazorac cream [package insert]. Exton, PA: Almirall, LCC.; August 2019.\n9. Tazorac gel [package insert]. Irvine, CA: Allergan; April 2018.\n10. Fabior [package insert]. Raleigh, NC. Mayne Pharma LLC.; February 2023.\n11. Altreno [package insert]. Bridgewater, NJ: Bausch Health US, LCC.; March 2020.\n12. Aklief cream [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; October 2023.\n© 2024 UnitedHealthcare Services, Inc.\n2\n13. Arazlo [package insert]. Bridgewater, NJ: Bausch Health Companies Inc.; August 2023.\nProgram Prior Authorization/Notification – Topical Retinoid Products\nChange Control\nDate Change\n11/2013 Added Fabior\n7/2013 Reformatted to align with template; added list of medical conditions;\nupdated references\n8/2014 Annual Review. Updated reference.\n7/2015 Annual Review. Updated reference.\n6/2016 Annual Review. Clarified cosmetic purpose question to indicate solely\nfor cosmetic purposes.\n2/2017 Updated to reflect exclusions.\n2/2018 Annual review. Updated references. Clarified non-cosmetic examples.\n1/2019 Added Altreno as target medication. Updated references.\n1/2020 Added Aklief and removed Tretin-X (discontinued). Updated\nreferences.\n6/2020 Removed generic Retin-A from criteria. Only Brand Retin-A will\nrequire notification.\n4/2021 Added Arazlo as target medication. Updated references.\n4/2022 Annual Review. Corrected spelling of conditions in table. Updated\nAtralin to reflect exclusion.\n10/2023 Annual review. Updated references.\n10/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}